Conference Call with Ipca Laboratories Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ipca Laboratories announced Q2FY24 results: Standalone Net Total Income up 11% at Rs 1,698.81 crore. Consolidated Net Total Income up 27% at Rs 2,072.51 crore. Indian formulations income is up 10 % at Rs 844.99 crore. Exports Income is up 14 % at Rs 720.72 crore. Standalone EBITDA margin (before forex (gain)/loss, other income, and Unichem acquisition cost) at 20.86% in Q2FY24 as against 18.85% in Q2FY23. Consolidated EBITDA margin (before forex (gain)/loss, other income, and Unichem acquisition cost) at 17.64% in Q2FY24 as against 17% in Q2FY23. Standalone Net Profit at Rs 162.13 crore down 2%. Consolidated Net Profit at Rs 145.06 crore up 1%. The Board has declared an interim dividend of Rs 21- per share (200%). Result PDF